Skip to main content
. 2022 Aug 23;2022:3132941. doi: 10.1155/2022/3132941

Figure 2.

Figure 2

Clinical outcome stratified by the CD33 rs12459419 polymorphism for patients treated with GO during the consolidation phase (a–h). (a) Overall survival (OS). (b) Relapse-free survival (RFS). (c–h) OS and RFS according to CD33 rs12459419 polymorphism and genetic risk. (c and d) OS and RFS in the favorable group; (e and f) OS and RFS in the intermediate group; and (g and h) OS and RFS in the adverse group.